CDC-RFA-FT-23-0069: Centers for Outbreak Analytics and Disease Modeling
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - CFA notices from 2023.
Centers for Disease Control - CFA offered grants to any type of organization. It expected to make about 13 awards worth $263 million in total. Applications closed on July 14, 2023.
From the official notice on Grants.gov, last changed June 2, 2023. Checked November 7, 2026.
- Total funding$263 million
- Expected awards13
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 14, 2023 |
|---|---|
| Deadline | July 14, 2023 |
| Archived by Grants.gov | August 13, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Eligible applicants are permitted to apply jointly for funding across multiple jurisdictions (e.g., multiple states, multiple local jurisdictions, border areas, Tribes and state/local jurisdictions). Bona fide agents are eligible to apply. For more information about bona fide agents, please see the CDC webpage on Expediting the Federal Grant Process with an Administrative Partner located at https://www.cdc.gov/publichealthgateway/grantsfunding/expediting.html#Q2.
Is this a realistic fit?
- Most of the program's money (84% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This new CDC cooperative agreement will develop a network of innovators to design, prototype, test, and scale innovative capabilities for improving analytics, modeling and forecasting to support decision makers during outbreaks of infectious diseases (both known and newly emerging) in the United States. The purpose of this cooperative agreement program is to save lives through improving public health response to disease threats. The primary objective of the cooperative agreement is to enhance communication and collaboration between innovators, integrators, and implementers in analytic methods with public health partners at federal, state, territorial, local and tribal levels to improve outbreak response through outbreak analytics and disease modeling. Partnership and collaboration between academia, public health, health care and the private sector is at the core of this funding opportunity.
Who has won Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics grants before
From fiscal 2021 to 2025, Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics (93.823) awarded $138 million across 14 grant awards, an average of $9.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Texas at Austin | Texas | 1 | $14.6 million |
| The Johns Hopkins University | Maryland | 1 | $12.6 million |
| International Responder Systems, LLC | Maryland | 1 | $11.3 million |
| Carnegie-Mellon University | Pennsylvania | 1 | $10.6 million |
| Regents of the University of Michigan | Michigan | 1 | $10.6 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-FT-23-0069 still open?
No. It closed on July 14, 2023.
Who can apply for Centers for Outbreak Analytics and Disease Modeling?
Centers for Disease Control - CFA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Centers for Outbreak Analytics and Disease Modeling?
Closed July 14, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $263 million in total across about 13 awards.
Who has won Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics grants before?
The largest recipients over five fiscal years were University of Texas at Austin, The Johns Hopkins University, International Responder Systems, LLC. The program made 14 awards worth $138 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)